Abstracts tagged "gout"

Abstract Number: 160 • 2014 ACR/ARHP Annual Meeting
All Men with Gout Should be Screened for Erectile Dysfunction
Naomi Schlesinger¹, Diane C. Radvanski² and John Kostis³, ¹Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, ²Department of Medicine, Division of Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ³Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose Erectile dysfunction (ED) is common in the general population. The likelihood of ED increases progressively with age; however, it is not an inevitable consequence…
Abstract Number: 1873 • 2014 ACR/ARHP Annual Meeting
Food Sources of Protein and Risk of Incident Gout in the Singapore Chinese Health Study
Gim Gee Teng^1,2, An Pan³, Jian-Min Yuan⁴ and Woon-Puay Koh^3,5, ¹Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, ²Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ³Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, ⁴Division of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute, and Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁵Duke-NUS Graduate Medical School Singapore, Singapore, Singapore

Background/Purpose: The Health Professional Follow up Study in Caucasian men showed that intakes of meat and seafood increased risk of gout, while dairy products, especially…
Abstract Number: 157 • 2014 ACR/ARHP Annual Meeting
Can We Diagnose Acute Gout without Joint Aspiration? Results of a Prospective Study of 112 Patients Presenting with Acute Arthritis
Pascal Zufferey, Roxana Valcov, Isabelle Fabreguet, Alexandre Dumusc and Alexander So, DAL, RHU/CHUV, Lausanne, Switzerland
Background/Purpose The gold standard for the diagnosis of acute MSU induced arthritis is crystal identification by microscopy after joint aspiration. Alternative diagnostic tools that have…
Abstract Number: 160 • 2013 ACR/ARHP Annual Meeting
Association Analysis Of The Organic Anion Transporter 4 and Urate Transporter 1 Locus With Gout In New Zealand Case-Control Sample Sets Reveals Multiple Ancestral-Specific Effects
Tony R. Merriman¹, Amanda Phipps-Green¹, Jade E. Hollis-Moffatt², Marilyn E. Merriman¹, Ruth Topless¹, Grant Montgomery³, Brett Chapman³, Lisa K. Stamp⁴, Nicola Dalbeth⁵ and Tanya Flynn², ¹Department of Biochemistry, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Queensland Institute of Medical Research, Brisbane, Australia, ⁴University of Otago, Christchurch, New Zealand, ⁵Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: There are genetic variants in urate transporters SLC22A11 (OAT4) and SLC22A12 (URAT1) that influence serum urate levels in European Caucasian. However, there is no…
Abstract Number: 1723 • 2013 ACR/ARHP Annual Meeting
Lesinurad, An Inhibitor Of The Uric Acid Transporter URAT1 and a Potential Therapy For Gout, Requires URAT1 Phenylalanine 365 For High Affinity Inhibition
Philip K. Tan, David Hyndman and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout is caused by a lack of efficient excretion of uric acid, resulting in hyperuricemia and the formation of crystal deposits of uric acid. …
Abstract Number: 1190 • 2013 ACR/ARHP Annual Meeting
The Synergistic Effects Of Metabolic Syndrome Indicators and Hyperuricemia In Contributing To Cardiac Event Risk: A Cross-Sectional Examination Of The Nhanes III Data
Daniel A. Albert^1,2 and Sayyad Kyazimzade³, ¹Medicine/Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Rheumatology, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, ³The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, Lebanon, NH
Background/Purpose: The focus of this project is to assess the contribution of hyperuricemia and gout to the risk for cardiovascular events. In a preliminary analysis…
Abstract Number: 163 • 2013 ACR/ARHP Annual Meeting
The Frequency Of Single Nucleotide Polymorphisms In Urate Transporter Genes and Their Association With Uric Acid Concentration Based On Data From Genome-Wide Association Studies In The Korean Population
Chan-Nam Son¹, So-Young Bang², Sang-Cheol Bae³ and Jae-Bum Jun³, ¹Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ³Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Gouty arthritis is characterized by hyperuricemia, which results from overproduction of, or impaired renal excretion of, uric acid. Recently, interest has increased in renal…
Abstract Number: 1721 • 2013 ACR/ARHP Annual Meeting
A Prediction Tool for Incident Gout Among Those With Hyperuricemia
Liseth Siemons¹ and Eswar Krishnan², ¹Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ²Medicine, Stanford University, Palo Alto, CA
Background/Purpose: The most common form of inflammatory arthritis observed in men is gout, a condition characterized by hyperuricemia and deposition of uric acid crystals in…
Abstract Number: 1192 • 2013 ACR/ARHP Annual Meeting
Pharmacovigilance Update On Pegloticase For Treatment Refractory Gout: United States Clinical Experience Demonstrates The Value Of Serum Uric Acid Monitoring As a Biomarker Of Risk and Efficacy
Robert T. Keenan¹, Raymond L. Malamet², Tina L. Howson³ and Kenneth M. Bahrt⁴, ¹Rheumatology, Duke University, Durham, NC, ²Global Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ, ³Savient Pharmaceuticals, Inc., Bridgewater, NJ, ⁴Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: Pegloticase was approved in the US in late 2010 for patients with chronic gout refractory to xanthine oxidase inhibitors (XOIs). The clinical development program…
Abstract Number: 170 • 2013 ACR/ARHP Annual Meeting
Association Of BMI, 8 SNPs Reported To Be Related To Gout Phenotype and Their Interaction In Gout Incidence In Framingham Heart Study
Jasvinder A. Singh^1,2, Ana Vazquez³, Richard Reynolds³, Vinodh Srinivasasainagendra⁴, S. Louis Bridges Jr.⁵ and David Allison³, ¹Rheumatology, Birmingham VA, Birmingham, AL, ²Department of Medicine, University of Alabama, Tuscaloosa, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of alabama at birmingham, birmingham, AL, ⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: We aim to assess the association of 8 serum urate SNPs and BMI and their interactions with incident gout in a population-based cohort study. Methods:…
Abstract Number: 1194 • 2013 ACR/ARHP Annual Meeting
Enhanced IL-1β and IL-6 Production In Gout Patients Upon Stimulation With Mono Sodium Urate Crystals and Synergizing Agents Compared To Healthy Volunteers
Tania O. Crisan¹, Maartje Cleophas¹, Mihai G. Netea¹, Tim L. Jansen² and Leo A. Joosten³, ¹Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: Gout is an autoinflammatory disease characterized by the deposition of monosodium urate (MSU) crystals in the joints of hyperuricaemic patients and subsequent attacks of…
Abstract Number: 1193 • 2013 ACR/ARHP Annual Meeting
Target Tophus Size and Complete Response Rates In Patients Treated With Open-Label Pegloticase For Chronic Gout Refractory To Conventional Therapy
Robert T. Keenan¹, Nicola Dalbeth² and Herbert S. B. Baraf³, ¹Rheumatology, Duke University, Durham, NC, ²Medicine, University of Auckland, Auckland, New Zealand, ³Arthritis & Rheumatism Associates, PC, Wheaton, MD
Background/Purpose: Pegloticase, a methoxyPEG-conjugated mammalian recombinant uricase, has been approved in the US and EU for the treatment of chronic gout refractory to xanthine oxidase…
Abstract Number: 2661 • 2013 ACR/ARHP Annual Meeting
Physical Activity, Adiposity, and The Risk Of Gout In Women: The Nurses Health Study
Hyon Choi^1,2,3, Lindsay C Burns^4,5, Yuqing Zhang⁶, Sharan Rai¹ and Gary Curhan⁷, ¹Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁵Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, ⁶Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁷German Research Center for Environmental Health, Harvard Medical School, Boston, MA
Background/Purpose: There is a remarkable, increasing disease burden of gout and its associated cardiovascular (CV)-metabolic comorbidities in the US. While the benefits of physical exercise…
Abstract Number: 1195 • 2013 ACR/ARHP Annual Meeting
Sex Differences In Gout Evaluation and Management
Leslie R. Harrold¹, Carol Etzel², Allan Gibofsky³, Joel M. Kremer⁴, Michael H. Pillinger⁵, Kenneth G. Saag⁶, Naomi Schlesinger⁷, Robert Terkeltaub⁸, Vanessa Cox² and Jeffrey D. Greenberg⁹, ¹University of Massachusetts Medical School, Worcester, MA, ²CORRONA, Inc, Southborough, MA, ³Medicine and Public Health, Hospital for Special Surgery, New York, NY, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷Medicine, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, ⁸Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁹Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY
Background/Purpose: Little is known regarding the evaluation, characteristics and management of women with gout. To characterize potential gender differences, we therefore compared clinical manifestations and…
Abstract Number: 1173 • 2013 ACR/ARHP Annual Meeting
A Clinically Significant Interaction Between Furosemide and Allopurinol: Potential Implications for Clinical Practice
Lisa K. Stamp¹, Claudia Knake² and Andrew Bahn², ¹Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ²Physiology, University of Otago, Dunedin, New Zealand
Background/Purpose: The xanthine oxidase (XO) inhibitor allopurinol is the most commonly used urate lowering therapy in gout. Allopurinol is metabolized to oxypurinol, which is responsible…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.